Bullfrog AI (BFRG) Competitors

$0.63 +0.01 (+1.51%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$0.63 0.00 (0.00%)

As of 08:37 AM Eastern

BFRG vs. VIRI, BTAI, NNVC, RNTX, and APLM

Should you buy Bullfrog AI stock or one of its competitors? MarketBeat compares Bullfrog AI with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bullfrog AI include Virios Therapeutics (VIRI), BioXcel Therapeutics (BTAI), NanoViricides (NNVC), Rein Therapeutics (RNTX), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry.

How does Bullfrog AI compare to Virios Therapeutics?

Bullfrog AI (NASDAQ:BFRG) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics' return on equity of -130.33% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-273.24%	-208.55%
Virios Therapeutics	N/A	-130.33%	-115.00%

Bullfrog AI has a beta of -3, meaning that its share price is 400% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

In the previous week, Bullfrog AI had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Bullfrog AI and 1 mentions for Virios Therapeutics. Bullfrog AI's average media sentiment score of 1.44 beat Virios Therapeutics' score of 0.00 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Overall Sentiment
Bullfrog AI	Positive
Virios Therapeutics	Neutral

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 25.2% of Bullfrog AI shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Virios Therapeutics has lower revenue, but higher earnings than Bullfrog AI. Virios Therapeutics is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$116.67K	68.38	-$6.50M	-$0.63	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

Bullfrog AI and Virios Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Bullfrog AI compare to BioXcel Therapeutics?

Bullfrog AI (NASDAQ:BFRG) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Bullfrog AI has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -10,887.38%. BioXcel Therapeutics' return on equity of 0.00% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-273.24%	-208.55%
BioXcel Therapeutics	-10,887.38%	N/A	-181.48%

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 824.37%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 25.2% of Bullfrog AI shares are owned by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Bullfrog AI had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 2 mentions for Bullfrog AI and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.89 beat Bullfrog AI's score of 1.44 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bullfrog AI	Positive
BioXcel Therapeutics	Very Positive

Bullfrog AI has higher earnings, but lower revenue than BioXcel Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$116.67K	68.38	-$6.50M	-$0.63	N/A
BioXcel Therapeutics	$640K	50.35	-$69.90M	-$6.71	N/A

Bullfrog AI has a beta of -3, meaning that its share price is 400% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Summary

BioXcel Therapeutics beats Bullfrog AI on 10 of the 16 factors compared between the two stocks.

How does Bullfrog AI compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.48	N/A
Bullfrog AI	$116.67K	68.38	-$6.50M	-$0.63	N/A

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 3.6% of NanoViricides shares are held by insiders. Comparatively, 25.2% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, NanoViricides and NanoViricides both had 2 articles in the media. Bullfrog AI's average media sentiment score of 1.44 beat NanoViricides' score of 0.65 indicating that Bullfrog AI is being referred to more favorably in the news media.

Company	Overall Sentiment
NanoViricides	Positive
Bullfrog AI	Positive

NanoViricides' return on equity of -87.90% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Bullfrog AI	N/A	-273.24%	-208.55%

NanoViricides has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Bullfrog AI has a beta of -3, meaning that its stock price is 400% less volatile than the broader market.

Summary

NanoViricides beats Bullfrog AI on 7 of the 12 factors compared between the two stocks.

How does Bullfrog AI compare to Rein Therapeutics?

Bullfrog AI (NASDAQ:BFRG) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Bullfrog AI has higher revenue and earnings than Rein Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$116.67K	68.38	-$6.50M	-$0.63	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.96	N/A

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 25.2% of Bullfrog AI shares are owned by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rein Therapeutics has a consensus target price of $8.00, indicating a potential upside of 589.66%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Rein Therapeutics had 2 more articles in the media than Bullfrog AI. MarketBeat recorded 4 mentions for Rein Therapeutics and 2 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.44 beat Rein Therapeutics' score of 0.63 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Overall Sentiment
Bullfrog AI	Positive
Rein Therapeutics	Positive

Bullfrog AI's return on equity of -273.24% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-273.24%	-208.55%
Rein Therapeutics	N/A	-510.35%	-56.38%

Bullfrog AI has a beta of -3, meaning that its share price is 400% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Summary

Rein Therapeutics beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.

How does Bullfrog AI compare to Apollomics?

Apollomics (NASDAQ:APLM) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Apollomics had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 3 mentions for Apollomics and 2 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.44 beat Apollomics' score of 0.96 indicating that Bullfrog AI is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Positive
Bullfrog AI	Positive

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 25.2% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Apollomics' return on equity of 0.00% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Bullfrog AI	N/A	-273.24%	-208.55%

Bullfrog AI has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.59	-$10.94M	N/A	N/A
Bullfrog AI	$116.67K	68.38	-$6.50M	-$0.63	N/A

Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Bullfrog AI has a beta of -3, meaning that its stock price is 400% less volatile than the broader market.

Summary

Apollomics beats Bullfrog AI on 6 of the 10 factors compared between the two stocks.

Get Bullfrog AI News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRG vs. The Competition

Export

Metric	Bullfrog AI	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.86M	$1.44B	$6.31B	$12.28B
Dividend Yield	N/A	N/A	2.79%	5.30%
P/E Ratio	-1.00	64.77	21.03	25.58
Price / Sales	68.38	6.18	552.34	78.22
Price / Cash	N/A	23.25	42.94	55.34
Price / Book	3.32	5.19	9.83	6.66
Net Income	-$6.50M	-$54.76M	$3.55B	$333.63M
7 Day Performance	-3.03%	-2.67%	-0.52%	-0.12%
1 Month Performance	-37.62%	5.65%	1.20%	3.93%
1 Year Performance	-64.31%	-4.88%	41.25%	36.07%

Bullfrog AI Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRG Bullfrog AI	0.644 of 5 stars	$0.63 +1.5%	N/A	-67.2%	$7.86M	$116.67K	N/A	4	Positive News Short Interest Decrease
VIRI Virios Therapeutics	N/A	$1.69 +2.4%	N/A	-64.4%	$32.55M	N/A	N/A	5
BTAI BioXcel Therapeutics	2.5994 of 5 stars	$1.19 -0.8%	$11.00 +824.4%	-16.8%	$32.49M	$640K	N/A	90	Positive News
NNVC NanoViricides	0.5506 of 5 stars	$1.50 +0.7%	N/A	+37.6%	$32.39M	N/A	N/A	20
RNTX Rein Therapeutics	3.2795 of 5 stars	$1.12 -2.6%	$8.00 +614.3%	-40.8%	$32.24M	N/A	N/A	9	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRG) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bullfrog AI (BFRG) Competitors

BFRG vs. VIRI, BTAI, NNVC, RNTX, and APLM

How does Bullfrog AI compare to Virios Therapeutics?

Summary

How does Bullfrog AI compare to BioXcel Therapeutics?

Summary

How does Bullfrog AI compare to NanoViricides?

Summary

How does Bullfrog AI compare to Rein Therapeutics?

Summary

How does Bullfrog AI compare to Apollomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG vs. The Competition

Bullfrog AI Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bullfrog AI (BFRG) Competitors

BFRG vs. VIRI, BTAI, NNVC, RNTX, and APLM

How does Bullfrog AI compare to Virios Therapeutics?

Do analysts prefer BFRG or VIRI?

Is BFRG or VIRI more profitable?

Which has more risk & volatility, BFRG or VIRI?

Does the media refer more to BFRG or VIRI?

Do insiders & institutionals have more ownership in BFRG or VIRI?

Which has preferable valuation & earnings, BFRG or VIRI?

Summary

How does Bullfrog AI compare to BioXcel Therapeutics?

Is BFRG or BTAI more profitable?

Do analysts recommend BFRG or BTAI?

Do insiders and institutionals hold more shares of BFRG or BTAI?

Does the media prefer BFRG or BTAI?

Which has better earnings & valuation, BFRG or BTAI?

Which has more risk & volatility, BFRG or BTAI?

Summary

How does Bullfrog AI compare to NanoViricides?

Do analysts recommend NNVC or BFRG?

Which has stronger valuation & earnings, NNVC or BFRG?

Do institutionals & insiders hold more shares of NNVC or BFRG?

Does the media refer more to NNVC or BFRG?

Is NNVC or BFRG more profitable?

Which has more risk and volatility, NNVC or BFRG?

Summary

How does Bullfrog AI compare to Rein Therapeutics?

Which has higher earnings & valuation, BFRG or RNTX?

Do institutionals and insiders believe in BFRG or RNTX?

Do analysts rate BFRG or RNTX?

Does the media favor BFRG or RNTX?

Is BFRG or RNTX more profitable?

Which has more volatility & risk, BFRG or RNTX?

Summary

How does Bullfrog AI compare to Apollomics?

Do analysts rate APLM or BFRG?

Does the media favor APLM or BFRG?

Do insiders & institutionals believe in APLM or BFRG?

Is APLM or BFRG more profitable?

Which has stronger earnings and valuation, APLM or BFRG?

Which has more risk & volatility, APLM or BFRG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG vs. The Competition

Bullfrog AI Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools